IMU Biosciences has raised $53 million in a Series A financing round, pledging to use the funds to change understanding, diagnosis and treatment of disease. The biotechnology company has built what it claims to be the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026 through access to patient samples and population […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!